Replies to post #12495 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Remind me again why LFB and GTC have decided to produce [rFVIIa]<

1. NovoSeven is a blockbuster.

2. NovoSeven goes off-patent fairly soon (2011 in the US).

3. GTC can produce rFVIIa more cheaply than Novo Nordisk (or anyone else).

4. A less expensive rFVIIa product will boost demand for prophylactic use in rich countries and for any use in poorer countries.